BRAF and melanoma: The responsiveness of NRAS-driven melanomas to targeted therapies is even worse, as BRAF inhibitors are generally inapplicable in this scenario, while MEK inhibitors alone do not offer significant improvements over conventional chemotherapy in the overall survival or the safety profiles [91,92].